The U.S. Food and Drug Administration late Thursday approved a new kind of drug to treat schizophrenia, a breakthrough after 70 years of incremental innovation that appears to avoid side effects ...

Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study ...

About a third of people with schizophrenia are resistant to conventional antipsychotic treatment. The current "pharmaceutical arsenal is limited". Clinical trials for new medications are expensive ...

While antipsychotics can be effective for some patients, they come with well-known side effects, including an increased risk ...

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

A new study conducted by researchers at the University ... It found that residents who were given antipsychotic medications showed a significant worsening of their behaviors.

Researchers from the National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, Technology ...

The FDA approval of Alkermes' new antipsychotic drug Lybalvi couldn't have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly ...

A new study by researchers at the University of Waterloo demonstrates that antipsychotic medications significantly worsened behavior in nursing home residents. “The proportion of long-term care ...

Opens in a new tab or window In a review of studies involving children and adolescents taking antipsychotics, a new systematic literature review found rates of TD between 5% and 20%. Risk factors ...

CMS has released its official 2025 mission and priorities document outlining its roadmap for state survey agencies Monday.